? Top themes this week: Alzheimer's drug, promising treatment for type 2 diabetes and obesity and innovative mass spec method

? Alzheimer’s drug milestone “bittersweet” for certain patients

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first treatment for Alzheimer’s in Great Britain that has shown some efficacy in slowing disease progression. Lecanemab is authorised to treat adults with early Alzheimer’s.

? Harnessing the GLP-1R medicine wave

Based on their rising popularity to treat type 2 diabetes and obesity, GlobalData has predicted that sales of glucagon-like peptide-1 receptor (GLP-1R) drugs will increase fourfold to an estimated $142 billion by 2030.

Considering the 11 approved GLP-1R drugs “generated $37.2 billion” last year, two key players in the market, namely 诺和诺德 and?Eli Lilly and Company,?are set to lead the market, the analytics company forecasts: “collectively capturing 94 percent of the total 2030 GLP-1R sales”.

? Innovative mass spec method may improve oligonucleotide therapeutic analysis

Researchers have developed a novel reverse-phase liquid chromatography–mass spectrometry (RP-LC-MS) method that does not require ion pairing reagents. This approach is suitable for use during development of oligonucleotide therapeutics.

Using ammonium bicarbonate (ABC) as the mobile phase additive in nonIP-RP-LC/MS was beneficial, the authors wrote, as carbonate and ammonium ions being present is “crucial”. Lumasiran was highlighted as an example of using the method for bioanalysis of a variety of natural or chemically modified oligonucleotides.

During this virtual panel, industry experts will explore the latest innovations and major challenges of drug formulation in the pharmaceutical industry. Discover the latest advances being used by drug formulators in the pharmaceutical industry in 2024 and learn about approaches that can support manufacturers, ensure optimal product quality and aid patient compliance